Chemist + Druggist is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Watson-Actavis deal will 'strengthen' support to UK pharmacists

Business US manufacturer Watson Pharrmaceuticals has acquired Actavis in a £3.45 billion deal that Actavis generics director Michael Cann (pictured) hopes will strengthen the company's relationship with pharmacists.

The acquisition of Actavis by US company Watson Pharmaceuticals will "strengthen" the support Actavis provides to UK pharmacists, generics director Michael Cann has told C+D

Mr Cann said Actavis would continue its policy to ensure that "pharmacists have access to our medicines off patent at day one or as early as possible", following the £3.45 billion (€4.25bn) acquisition announced last month, which makes the combined group the third largest global generics company.

Actavis generics director Michael Cann hopes the Actavis-Watson deal will strengthen its relationship with pharmacists

More acquisition news

Watson Pharmaceuticals to adopt Actavis brand name       after acquisition

Alliance Boots buys £56m stake in Chinese wholesaler

Stefano Pessina: Walgreens deal ‘will not kill Boots'

The appointment of former Actavis CEO Siggi Olafsson as president of Watson in April meant the company had "a good insight into the UK" and fully supported its business model, said Mr Cann.

Combining the two companies would "hopefully strengthen" its relationship with pharmacists, he added.

"We need the appropriate relationship with retail pharmacy and we need to have those relationships through our sales people in order to develop the services that they need to support their dispensing of medicines."

Watson announced it would change its name to Actavis, following the acquisition of the generics manufacturer in October.

The company has a combined portfolio of 900 products across generics, hospital medicines and consumer healthcare and estimates that Actavis packs account for one in seven of all generics dispensed in the UK.

There were no immediate plans to alter its medicine packaging, the manufacturer said, although this would be decided in a re-branding programme next year.

Do you think the deal will strengthen your relationship with Actavis?

Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook


Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts